Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
N/A
2(33.3%)
6Total
Phase 1(4)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06124508Not ApplicableRecruiting

PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors

Role: collaborator

NCT04881916Active Not Recruiting

Immune and Genomic Markers in ALK+ NSCLC

Role: collaborator

NCT05558904Phase 1Recruiting

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Role: collaborator

NCT06080061Phase 1Recruiting

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Role: collaborator

NCT03546361Phase 1Active Not Recruiting

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Role: collaborator

NCT05304390Not ApplicableTerminated

A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle

Role: collaborator

NCT05826756Unknown

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

Role: lead

NCT05430009Phase 1Recruiting

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Role: collaborator

All 8 trials loaded